NCT05323019 (ZYL-730-01) is a Phase 2 clinical trial of Psychotherapy in Treatment Resistant Major Depressive Disorder, sponsored by Zylorion Health.

Who is sponsoring NCT05323019?

NCT05323019 is sponsored by Zylorion Health.

What drugs are being tested in NCT05323019?

Interventions in NCT05323019: Psychotherapy, Treatment as Usual, Intranasal Ketamine (esketamine).

What condition does NCT05323019 study?

NCT05323019 studies Treatment Resistant Major Depressive Disorder.

Is NCT05323019 still recruiting?

NCT05323019 is currently terminated. Last updated 24 March 2023.

Last reviewed 2023-03-24 · How we verify

NCT05323019: ZYL-730-01

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Repeated Intranasal Esketamine Plus Almond Therapy in Patients With Treatment Resistant Depression

Terminated Phase 2 Last updated 24 March 2023

What this trial tests

Phase 2 trial testing Psychotherapy in Treatment Resistant Major Depressive Disorder in 6 participants. Terminated before completion.

Timeline

13 October 2022

Primary endpoint
1 February 2023

1 February 2023

Quick facts

Lead sponsor	Zylorion Health
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	6
Start date	13 October 2022
Primary completion	1 February 2023
Estimated completion	1 February 2023
Sites	1 location across Canada

Drugs / interventions tested

Psychotherapy
Treatment as Usual
Intranasal Ketamine (esketamine) — full drug profile →

Conditions studied

Treatment Resistant Major Depressive Disorder — all drugs for Treatment Resistant Major Depressive Disorder →

Sponsor

Zylorion Health — full company profile →

Who can join

Adults 18 to 64, any sex, with Treatment Resistant Major Depressive Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To examine the efficacy of Almond Therapy compared to Treatment as Usual when used in addition to an approved version of intranasal esketamine.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Psychotherapy

Trials testing the same drug.

NCT06827054 — Psilocybin With Psychotherapy for Improving Chronic Pain in Cancer Patients Requiring Opioids · Phase 2 · not yet recruiting
NCT07336238 — Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or · Phase 2 · recruiting
NCT07507370 — CARED : A Novel Rapid Treatment Paradigm for Depression · NA · not yet recruiting
NCT07250893 — Resolving Early Life Stress: Psychotherapy Outcomes and Neurobiology in Complex Depression · NA · recruiting
NCT06353282 — MDMA-Assisted Psychotherapy for Treatment Resistant PTSD in Adolescents · Phase 2 · withdrawn

Other Zylorion Health trials

Trials by the same sponsor.

NCT05438758 — Repeated Intranasal Esketamine Plus Almond Therapy in Participants With Treatment Resistant Depressive Disorder - 3 Mont · Phase 2 · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05323019 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zylorion Health
Last refreshed: 24 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05323019.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing